Abstract

Pulmonary rehabilitation (PR) is a critical component of comprehensive care for individuals with chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma. Inflammation plays a central role in the pathophysiology of these conditions, leading to airway obstruction, mucus hypersecretion, and reduced quality of life. This article explores emerging anti-inflammatory drugs in the context of pulmonary rehabilitation, focusing on their mechanisms of action, clinical efficacy, and potential integration into rehabilitation programs. By addressing the inflammatory component of respiratory diseases, these agents may enhance functional outcomes and improve overall patient well-being